Loranta

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loranta

Quick Facts

Property Description
Active Ingredient (INN) Losartan (often as Losartan Potassium)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Primary Indication High blood pressure (Hypertension)
Primary Form Oral film-coated tablet
Distinguishing Feature Unique uricosuric (uric acid-lowering) effect

What Type of Medicine is Loranta and What Class Does it Belong To?

Loranta is a prescription cardiovascular medication containing the active ingredient losartan, which is the first clinically available drug in the Angiotensin II Receptor Blocker (ARB) pharmacological class. This classification is clinically recognized for selectively targeting the body's renin-angiotensin system (RAS), which is instrumental in blood pressure regulation. As an ARB, it acts as an antihypertensive agent used to help relax blood vessels. Losartan’s introduction established this class of drug as a fundamental component of guideline-directed medical therapy.


Is Loranta a Synthetic Compound or Naturally Derived?

The active substance in Loranta, losartan potassium, is a wholly synthetic pharmaceutical compound created through targeted medicinal chemistry. Its synthetic origin ensures consistent chemical purity and reliable manufacturing standards. Losartan possesses a unique uricosuric effect, meaning it promotes the excretion of uric acid through the urine—a differentiating property among ARBs that can be beneficial for patients who also manage high uric acid levels. This pharmacological property allows losartan to reduce serum uric acid levels. The final product is formulated as an oral tablet containing the active salt and common excipients.


What Conditions is Loranta Generally Prescribed For?

Loranta is broadly used to manage chronic cardiovascular conditions, predominantly high blood pressure (hypertension). It is included on the WHO List of Essential Medicines, reflecting its foundational role in global public health for controlling chronic disease. A typical use scenario involves long-term, once-daily administration to maintain controlled blood pressure levels and reduce the overall risk of serious health issues like stroke. It is also used for kidney protection in patients with Type 2 diabetes and hypertension. This therapy is focused on managing the conditions and does not involve detailed usage instructions, which are covered in a separate section.

Regulatory References

  1. Losartan - StatPearls - NCBI Bookshelf
  2. LOSARTAN POTASSIUM tablet - DailyMed
  3. Losartan: MedlinePlus Drug Information

What side effects are possible with Loranta?

Possible Side Effects and Safety Information

The safety profile for Loranta (Losartan INN) is categorized by regulatory agencies based on the documented frequency and type of adverse reactions observed in clinical trials and post-marketing surveillance. This information strictly details the drug’s officially documented risks, without providing instruction or medical advice.

Officially Documented Adverse Reactions

Adverse effects are grouped by their incidence and the body system affected. Common reactions, occurring in ge2% of clinical trial participants, include dizziness (a Nervous System Disorder), upper respiratory infection, nasal congestion, and back pain (Musculoskeletal and Connective Tissue Disorder). Other effects, classified as less common or post-marketing, may include headache, insomnia, abdominal pain, nausea, and rash.

Serious Safety Considerations and Constraints

Certain severe adverse reactions are explicitly highlighted in the regulatory documentation:

  • Fetal Toxicity: Losartan is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus.
  • Angioedema: Serious swelling of the face, lips, tongue, and/or throat has been reported and requires immediate attention.
  • Hyperkalemia: The medication can increase serum potassium levels, necessitating periodic monitoring of electrolytes in susceptible individuals.
  • Hypotension and Renal Function: Symptomatic low blood pressure may occur, particularly in volume-depleted patients. Deterioration of renal function is documented, especially in patients with pre-existing conditions like renal artery stenosis.

Safety limitations apply to specific patient groups. Use is restricted in individuals with severe hepatic impairment due to increased drug concentrations. Furthermore, dizziness is noted as being more common when first starting treatment. Regulatory labels also restrict use alongside aliskiren in patients with diabetes.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations of Losartan overdose and the actions mandated by regulatory authorities, based on the product’s prescribing information.

Overdose Scope

The most likely clinical presentations of overdose are severe hypotension (low blood pressure) and changes in heart rate, typically tachycardia (fast heart rate). Bradycardia (slow heart rate) is also a documented possibility that may occur due to parasympathetic stimulation. The primary severe outcome requiring intervention is symptomatic hypotension.

Overdose-Context Constraints
Antidote: No specific antidote is known for Losartan or its active metabolite.
Removal: Losartan and its active metabolite cannot be removed from the body by hemodialysis.

Emergency Actions Mandated by Regulation

Immediate medical attention must be sought for any suspected overdose or if signs of severe low blood pressure are manifested. The official regulatory text dictates that if symptomatic hypotension develops, supportive treatment should be instituted. This management generally requires close medical observation and continuous monitoring, consistent with a severe presentation of cardiovascular instability.

Therapeutic Uses of Loranta

Main Uses and Therapeutic Intent

Loranta, which contains the active ingredient losartan, belongs to a class of medications known as angiotensin II receptor blockers (ARBs). It is primarily used to manage conditions related to the cardiovascular system and renal function. The medication works by blocking the action of angiotensin II, a natural substance in the body that causes blood vessels to tighten. By relaxing these vessels, the medication helps to improve blood flow and reduce the workload on the heart.

Management of Hypertension

The primary application of this medication is the management of high blood pressure (hypertension). Maintaining blood pressure within a target range is a key component in reducing the long-term risk of cardiovascular events. By helping to lower elevated blood pressure, the medication assists in preventing damage to various organs, including the heart, brain, and kidneys.

Cardiovascular Protection in Specific Patient Groups

Beyond general blood pressure management, this medication is utilized for its protective effects on the cardiovascular system. In patients who have both hypertension and left ventricular hypertrophy (a thickening of the walls of the heart's main pumping chamber), the medication is used to reduce the risk of stroke. This benefit is linked to the drug's ability to manage pressure loads on the heart muscle.

Renal Protection in Type 2 Diabetes

Loranta is also indicated for the treatment of kidney disease in patients with type 2 diabetes and a history of hypertension. In this context, it is used to slow the progression of diabetic nephropathy (kidney damage caused by diabetes). It helps reduce the presence of albumin in the urine, which is often an early marker of kidney stress, thereby supporting long-term renal health in diabetic patients.

Expected Benefits

The therapeutic benefits of this medication center on long-term health maintenance and the prevention of complications associated with chronic conditions:

  • Blood Pressure Stability: Facilitates the attainment of consistent blood pressure levels.
  • Reduction of Stroke Risk: Provides targeted protection for hypertensive patients with specific heart muscle changes.
  • Kidney Preservation: Offers a specialized mechanism to delay the decline of kidney function in individuals with diabetes.
  • Improved Vascular Function: Promotes better circulation by preventing the narrowing of blood vessels.

Regulatory References

  1. NIH DailyMed official Losartan Indications

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Loranta (Losartan INN) — official regulatory information

Eligibility Scope

Classification Populations Condition/Context
Contraindicated Pregnant women (2nd and 3rd trimester); Severe hepatic impairment; Individuals with known hypersensitivity. Also prohibited for patients with Diabetes Mellitus or reduced kidney function (GFR < 60 mL/min/1.73 m^2) when taking Aliskiren.
Allowed Adults (18 years and older); Children 6 years and older. Pediatric use is established only for hypertension.
Not Recommended Women in the 1st trimester of pregnancy; Breastfeeding mothers; Children under 6 years of age. Also not recommended for patients with Primary Hyperaldosteronism or children with severe renal impairment (GFR < 30 mL/min/1.73 m^2).

Eligibility-Related Restrictions

  • Hepatic Impairment: Use is conditional in mild to moderate impairment; a lower starting dose is required based on regulatory labeling.
  • Volume Depletion: Eligibility is conditional; salt or volume depletion (e.g., from high-dose diuretics) must be corrected before administration.
  • Cardiovascular Conditions: Special caution and monitoring are indicated for patients with conditions like bilateral renal artery stenosis or aortic/mitral valve stenosis.

Eligibility Classifications (High-Level)

  • Eligibility severity classification (as defined in official documents): Contraindicated; Not Recommended; Conditional Use; Use Not Established.
  • Regulatory basis: SmPC / FDA Labeling / Prescribing Information.

The official regulatory documents define eligibility for Losartan by establishing absolute prohibitions based on reproductive status and organ function, such as the contraindication during late pregnancy and in severe hepatic impairment. Use is further delimited by age-group eligibility, permitting use for hypertension in children starting at six years old, while specific comorbidity and organ function restrictions require special regulatory caution or corrective action before use is allowed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Loranta's interaction profile is officially defined by specific pharmacodynamic risks and pharmacokinetic alterations, primarily affecting plasma concentrations of the active metabolite.


Interaction Type Interacting Substances/Context Official Statement of Risk
Formal Contraindication Aliskiren Contraindicated in patients with Type 2 Diabetes Mellitus due to increased risk of hypotension, hyperkalemia, and renal impairment (Dual RAS blockade).
Pharmacodynamic Risk Potassium-sparing diuretics (e.g., spironolactone), Potassium supplements, Potassium-containing salt substitutes Co-administration is formally noted to increase the risk of hyperkalemia (elevated serum potassium levels).
Pharmacodynamic Risk NSAIDs (including COX-2 inhibitors) Documented to reduce the antihypertensive effect and increase the risk of renal function deterioration, particularly in susceptible patients.
Pharmacokinetic Alteration Fluconazole (CYP2C9 inhibitor) Significantly decreases the plasma exposure ( AUC) of the more potent active metabolite while increasing the AUC of losartan.
Toxicity Risk Lithium Co-administration is associated with reported increases in serum lithium concentrations and subsequent risk of lithium toxicity.
Population-Specific Note Hepatic Impairment Results in significantly increased plasma concentrations and exposure of both losartan and its active metabolite due to slower clearance.

Official regulatory documents classify these as clinically significant interactions that establish strict boundaries for co-administration. The profile mandates an explicit prohibition on the combination with Aliskiren under certain conditions and requires specific monitoring for agents that affect potassium balance, renal function, or the drug's metabolic pathway.

Mechanism of Action

Selective Angiotensin II Receptor Blockade

Loranta exerts its primary mechanism by acting as a selective antagonist of the Angiotensin II Type 1 ( AT1) receptor. It inhibits the hormone Angiotensin II from binding to these receptors in the blood vessels, heart, and adrenal glands. This targeted interference with the Renin-Angiotensin-Aldosterone System (RAAS) cascade directly inhibits the signaling that mediates vasoconstriction and promotes sodium and water retention.


Key Physiological Cascade Effects

Blocking the AT1 receptor initiates a mechanistic cascade leading to two primary physiological consequences. First, it prevents the smooth muscles in blood vessels from contracting, which results in vasodilation (widening of blood vessels). Second, it influences the Angiotensin II-driven release of aldosterone, resulting in increased sodium and water excretion by the kidneys. These combined effects influence systemic vascular resistance and plasma volume.


Active Metabolite for Sustained Modulation

The drug's activity involves its conversion into an active compound, EXP3174, via liver enzymes. Both the parent drug and the metabolite bind to the AT1 receptor, with the active metabolite exhibiting a higher affinity for the AT1 receptor and a longer plasma half-life. This dual action contributes to the sustained modulation of the RAAS pathway, influencing the prolonged physiological response.

Dosage and Administration Information

How to Use Loranta (Losartan INN) — Administration Guidelines

Losartan is a medication taken orally and is typically administered once daily. The tablet should be swallowed with a glass of water and can be taken with or without food. Consistency in daily timing is often recommended.

Dosing and Frequency

The standard adult starting dose is 50 mg once daily. Depending on the patient's condition and blood pressure response, the daily dose may be adjusted from 25 mg to a maximum of 100 mg, which may be given as a single daily dose or divided into a twice-daily regimen. For certain patients, such as those who may have low intravascular volume (e.g., due to high-dose diuretic use) or impaired liver function, a lower starting dose of 25 mg once daily is recommended.


Special Administration Rules

Age Group Administration Rule
Adults (General) Start at 50 mg once daily. Adjust up to 100 mg once or twice daily.
Elderly (over 75) Lower starting dose (25 mg) may be considered.
Pediatric (ge 6 years) Starting dose of 0.7 mg/kg once daily (up to 50 mg total).

Losartan is not recommended for children under 6 years of age. If a dose is missed, do not take a double dose to catch up. Instead, take the next scheduled dose at the usual time and continue the regular dosing schedule. Intravascular volume depletion should be corrected before starting Losartan, or a lower initial dose must be used.

Recent Clinical Evidence

Research evidence / Overview of studies for Loranta (Losartan INN)

Evidence for Use in Managing Chronic High Blood Pressure

Research examined Losartan primarily through large-scale, long-term randomized controlled trials (RCTs) and various meta-analyses compiling data from comparative studies. Outcomes monitored included changes in blood pressure, alongside long-term outcomes related to systemic or functional imbalance, such as the overall rates of major cardiovascular events.

Findings describe patterns observed in these studies, which monitored changes in blood pressure across the enrolled populations. Research highlights changes measured during the study period, contributing to the broader evidence landscape for managing this condition. Studies focusing on extended follow-up for certain high-risk adult groups are not fully established.


Evidence for Researching Kidney Outcomes in Type 2 Diabetes

The evidence for this condition was evaluated in pivotal, long-term, randomized trials specifically designed to assess kidney health. The outcomes captured phases of heightened symptom activity, using a combined measure that included biomarkers of kidney function decline, such as changes in serum creatinine, and the progression toward the need for renal replacement therapy.

Studies explored the progression of kidney disease over defined time intervals spanning several years. Findings indicate a difference in the rate of change in the composite renal outcome markers in the observed populations receiving Losartan, compared to a placebo. Research highlights changes measured during the study period, particularly regarding proteinuria (excess protein in the urine).


Evidence for Examining Cerebrovascular Outcomes with Left Ventricular Hypertrophy (LVH)

Research examined Losartan in patients with hypertension who also presented with evidence of Left Ventricular Hypertrophy (LVH). This was done via a pivotal, long-term randomized controlled trial that explored cardiovascular event rates compared to another common antihypertensive drug. Outcomes studied included the incidence of stroke (fatal and non-fatal) and the overall composite of cardiovascular events.

Data show patterns related to differences in the incidence of stroke when compared to the reference drug. Analysis of the data documented patterns of change in ECG measures related to LVH size in the studied population.


Research on Losartan's Associated Uric Acid Effect

This segment details the research that explored the differentiating property of Losartan related to uric acid. The evidence was derived from short-term comparative clinical trials and pharmacological studies that examined temporary physiological imbalance related to uric acid levels. Studies monitored a biomarker: the amount of uric acid in the blood and urine.

Studies report how uric acid levels evolved in the observed populations, generally indicating a change in serum uric acid levels. Research examined how these changes compared to those observed with other common antihypertensive drugs. This effect was observed in some studies and the research provides insight into short-term changes in this specific biomarker.

Key Studies & References

  1. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
  2. Label: LOSARTAN POTASSIUM tablet, film coated - DailyMed (FDA Drug Label)
  3. Losartan - WHO Model List of Essential Medicines (eEML)

Frequently Asked Questions (FAQ)

Common questions about Loranta (Losartan INN) (FAQ)

Q: Why do some people call Loranta a 'water pill' when it's not one?

A: Losartan is not classified as a diuretic, the type of drug commonly known as a 'water pill.' However, regulatory information explains that its mechanism of action leads to increased excretion of sodium and water by the kidneys. This physiological effect, which reduces fluid retention, can cause the drug to be commonly described using the term 'water pill.'

Q: How is Loranta different from other blood pressure medicines?

A: Official information indicates that Loranta belongs to the Angiotensin II Receptor Blocker (ARB) class of medications. Compared to ACE inhibitors, a related class of medication, official documentation notes a lower incidence of dry cough. Furthermore, clinical studies note that losartan has a unique property among ARBs called a uricosuric effect, meaning it promotes the excretion of uric acid.

Q: Will I have side effects right away or only after using Loranta for a while?

A: Official product information notes that certain side effects, such as dizziness or lightheadedness, are more commonly experienced when treatment is first started. However, regulatory documents do not provide a general timeline for the onset of all other less common adverse reactions, such as upper respiratory infection or back pain.

Q: Can Loranta cause a cough like some other blood pressure drugs?

A: Clinical studies summarized in regulatory documents indicate that losartan is generally not associated with causing a cough. This adverse effect is a known risk of a different class of blood pressure medicine, the ACE inhibitors. Official sources state that the incidence of cough with losartan is typically low.

Q: Do you have to avoid grapefruit juice when taking Loranta?

A: Official guidance notes that the use of grapefruit juice should be avoided while using losartan. Grapefruit can affect the way the body processes the medication, potentially altering the levels of the active drug and its metabolite in the bloodstream. This may influence the drug's effectiveness and the risk of side effects.

Q: What happens if I drink alcohol while using Loranta?

A: The official product information indicates that alcohol consumption may enhance the blood pressure-lowering effect of losartan. This effect increases the potential risk of symptomatic low blood pressure (hypotension), which may lead to side effects like dizziness, lightheadedness, or fainting.

Q: How quickly does Loranta start to lower blood pressure after the first pill?

A: Medication information indicates that the reduction in blood pressure may begin within the first week of starting treatment. However, the full therapeutic benefit of the medication in managing blood pressure is typically observed over a longer period, generally requiring three to six weeks of consistent use.

Q: How long does the effect of one dose of Loranta usually last?

A: Due to the sustained activity of both the main drug compound and its active metabolite, the effects of losartan are designed to be long-lasting. Official information notes that the drug is typically taken once daily to maintain a consistent blood pressure-lowering effect over a 24-hour period.

Q: Is Loranta generally considered safe for people with diabetes?

A: Losartan is officially indicated for helping to protect the kidneys in patients who have both Type 2 diabetes and hypertension. However, it is contraindicated for diabetic patients who are also taking the drug aliskiren, based on the documented risks of hyperkalemia and renal impairment.

Q: Why is it described that Loranta is for heart failure?

A: Losartan is a prescription medication that is officially described for use in certain contexts related to heart failure. According to regulatory data, the drug’s mechanism of blocking the Angiotensin II receptor helps to relax blood vessels and reduce fluid retention. These combined physiological actions work to ease the overall workload on the heart.

Q: Are there any long-term effects of using Loranta for many years?

A: Losartan is often used as a long-term treatment for chronic conditions like hypertension. Official safety documentation and regulatory-reviewed studies have assessed the drug over many years, primarily monitoring for major cardiovascular events, changes in kidney function, and potential electrolyte imbalances.

Q: Have there been recent studies about Loranta and kidney protection?

A: The primary evidence supporting the use of losartan for kidney protection comes from pivotal, long-term randomized trials. Regulatory documents primarily refer to the data collected from these landmark studies, which specifically assessed the health of the kidneys in patients with Type 2 diabetes and high blood pressure.

Q: What class of drug is Loranta and how does that affect its use?

A: Loranta belongs to the Angiotensin II Receptor Blocker (ARB) class of medications. This classification is used to understand the drug's role in cardiovascular risk. ARBs are widely recognized in published clinical guidelines as a fundamental component of comprehensive medical therapy for hypertension.

Q: Is Loranta effective for lowering blood pressure in all patient populations?

A: Clinical trials generally show that losartan is effective for lowering blood pressure across diverse groups. The official FDA drug label includes a note that antihypertensive drugs, including losartan, may exhibit a smaller average blood pressure effect in Black patients compared to other populations studied.

Q: Why are people with angioedema advised not to use Loranta?

A: Angioedema, characterized by serious swelling of the face, lips, tongue, or throat, is a rare but severe adverse reaction reported with losartan. Official warnings note that patients with a pre-existing history of angioedema related to an ARB or an ACE inhibitor are typically considered to be at an increased risk.

Q: Will Loranta interfere with my ability to drive or operate machinery?

A: Official guidance notes that due to the potential for dizziness or drowsiness, special attention is required before performing tasks like driving or operating heavy machinery. This effect is most notable after the first dose or following an increase in dosage.

Q: Do the side effects of Loranta eventually go away?

A: Medication guides indicate that side effects such as dizziness, lightheadedness, and fainting are most commonly observed when treatment is first initiated. Official sources do not provide a general assurance or definitive timeline for the resolution of all other common side effects that a patient may experience.

Q: Is Loranta considered a first-line treatment for high blood pressure in official guidelines?

A: Losartan belongs to the ARB class, which is considered an essential component of cardiovascular risk management. Official documents state that the selection of initial therapy should align with published clinical guidelines, where ARBs are often recommended as one of the primary classes for managing hypertension.

Q: What does official guidance say about stopping Loranta suddenly?

A: Official medication guidance notes that abruptly stopping this type of medication can lead to a rapid increase in blood pressure. This potential rebound effect is associated with an elevated risk of severe cardiovascular events.

Q: What is the significance of the black box warning (if any) mentioned for Loranta?

A: Losartan carries an FDA Boxed Warning, sometimes referred to as a Black Box Warning, regarding the risk of Fetal Toxicity. The warning states that if pregnancy is detected, the medication should be discontinued as soon as possible due to the risk of injury and death to the developing fetus.

Q: What types of research have been conducted on Loranta’s use in heart disease?

A: Regulatory review of losartan includes studies focused on major cardiovascular outcomes beyond just blood pressure control. This includes large-scale trials specifically examining patients with Left Ventricular Hypertrophy (LVH) to assess potential reduction in stroke risk, as well as long-term research on its use in heart failure.

Q: Is it true that Loranta is only for people with severe hypertension?

A: No, the official indication for losartan is the treatment of general high blood pressure, not solely severe cases. While the absolute benefits of blood pressure reduction may be greater for patients who are at higher overall cardiovascular risk, the drug is used across a range of hypertension severities.

How should Loranta be stored and disposed of?

How to Store and Dispose of Loranta (Losartan INN)?

Official regulatory guidance defines the mandatory conditions for storing and disposing of Losartan Potassium tablets to maintain product stability and safety.

Storage and Disposal Requirement Official Guideline
Storage Temperature Store at controlled room temperature, typically not exceeding 25 C or 30 C.
Protection Keep in the original, tightly closed container and protect from excess heat, light, and moisture.
Child Safety Mandatory: Keep the medication strictly out of the sight and reach of children and pets.
Prohibited Disposal Do not dispose of via wastewater (flushing down toilets or sinks).
Official Disposal Method Utilize community drug take-back programs or ask a pharmacist for advice on proper disposal.

These guidelines ensure the integrity of the synthetic Losartan compound and protect against accidental ingestion and environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loranta found in:

A-Z Index: